Astrea / News / Astrea has advised ArchiMed on its investment i...


Astrea has advised ArchiMed on its investment in Xpress Biologics

Firm news | Steven De Schrijver / Philippe Willemsens / Steve Tronckoe / Frederick Geldhof / Jonas Jespers

Lorem ipsum dolor sit amet,
consetetur sadipscing elitr,
sed diam nonumy eirmod
tempor invidunt ut labore et

Astrea has advised ArchiMed, a leading investment firm focused exclusively on the healthcare industries, on backing Xpress Biologics, a leading developer of systems and manufacturing processes for the production of plasmid DNA and protein therapeutics.

With the support of ArchiMed, Xpress Biologics will be able to take a bigger step in the expansion of its production and internationalizing.

We are proud of our contribution to ArchiMed its next step!

We wish ArchiMed and Xpress Biologics all the best in their partnership and growth.

Our full-service team was composed of our Corporate and M&A partner Steven De Schrijver, Philippe Willemsens, Steve Tronckoe, Frederick Geldhof and Jonas Jespers.